-
Lexicon Pharmaceuticals Shares Plunge On Proposed Public Offering
Wednesday, July 27, 2022 - 5:42pm | 167Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) shares dropped 18% in the after-hours session on commencing an underwritten public offering to offer and sell shares of its common stock, par value of $0.001. Lexicon intends to grant the underwriters a 30-day option to purchase...
-
Turning Point Secures Positive FDA Feedback For Planned Lung Cancer Drug Submission
Wednesday, July 27, 2022 - 4:45pm | 210Turning Point Therapeutics (NASDAQ: TPTX) has received positive feedback from the U.S. Food and Drug Administration (FDA) at a pre-New Drug Application (NDA) meeting completed in the second quarter. The pre-NDA meeting was convened to discuss its planned NDA for the lead asset Repotrectinib in...
-
FDA Accepts Lexicon's New Drug Application For Review In Heart Failure Setting
Wednesday, July 27, 2022 - 11:20am | 226The U.S. Food and Drug Administration (FDA) has accepted for review Lexicon Pharmaceuticals ‘ (NASDAQ: LXRX) New Drug Application (NDA) for sotagliflozin for the treatment of heart failure. The regulatory agency has assigned a standard review with a PDUFA target action date in May 2023. The...
-
LabCorp (LH) To Report Q2 Earnings: What's In The Cards?
Wednesday, July 20, 2022 - 11:35am | 1188Laboratory Corporation of America Holdings (NYSE: LH), also known as LabCorp, is slated to report second-quarter 2022 results on Jul 28, before market open. In the last reported quarter, the company's adjusted earnings of $6.11 exceeded the Zacks Consensus Estimate by 3.9%. The company beat...
-
New York Attorney General Says Teva Tried To Evade Accountability On Opioid Crisis: Report
Tuesday, July 12, 2022 - 7:50am | 386Reuters reported that New York's attorney general said Teva Pharmaceutical Industries Ltd (NYSE: TEVA) lied to evade accountability regarding its role in the state's opioid crisis. Teva was accused by Attorney General Letitia James, Nassau County, and Suffolk County of using...
-
Alibaba, Zoom Video And 76 Biggest Movers From Yesterday
Tuesday, July 12, 2022 - 5:35am | 2849Gainers Kaspien Holdings Inc. (NASDAQ: KSPN) shares climbed 161.9% to close at $6.81 on Monday on heavy volume amid mention of the stock on social media. Pliant Therapeutics, Inc. (NASDAQ: PLRX) shares surged 159% to close at $23.00 on Monday after the company said its treatment for Idiopathic...
-
Dow Dips Around 90 Points; La Jolla Pharmaceutical Shares Surge
Monday, July 11, 2022 - 2:42pm | 777U.S. stocks traded lower toward the end of trading as investors digested the recent jobs report for the month of June. The Dow traded down 0.30% to 31,242.86 while the NASDAQ fell 1.85% to 11,419.99. The S&P also fell, dropping, 0.92% to 3,863.48. Also check this: GameStop, Levi Strauss And 3...
-
Needham Previews Neurocrine's Upcoming Mid-Stage Data from Essential Tremor Study
Monday, July 11, 2022 - 2:20pm | 257Needham previews the upcoming Phase 2 data readout for Neurocrine Biosciences Inc's (NASDAQ: NBIX) NBI-827104, a t-type calcium channel blocker in essential tremor (ET), by mid-2022. The analyst notes that though NBI-827104 lags behind its competitors, the market...
-
Why These Casino Stocks Are Moving Lower, Here's 45 Stocks Moving In Monday's Mid-Day Session
Monday, July 11, 2022 - 12:11pm | 1605Gainers Pliant Therapeutics, Inc. (NASDAQ: PLRX) jumped 112.6% to $18.88 after the company said its treatment for Idiopathic Pulmonary Fibrosis was well tolerated in a Phase 2a study. La Jolla Pharmaceutical Company (NASDAQ: LJPC) gained 80.9% to $6.13 after Innoviva entered into a definitive...
-
Innoviva Bolsters Its Infectious Disease, Hospital Portfolio With La Jolla Deal
Monday, July 11, 2022 - 8:14am | 245Innoviva Inc (NASDAQ: INVA) has agreed to acquire La Jolla Pharmaceutical Company (NASDAQ: LJPC) for $5.95 per share, representing a premium of approximately 70% to the 30-day volume-weighted average price. Innoviva will also pay an incremental $0.28 per share for additional...
-
Alphabet, Dyne Therapeutics And 74 Biggest Movers From Yesterday
Wednesday, July 6, 2022 - 5:21am | 2473Gainers Enjoy Technology, Inc. (NASDAQ: ENJY) shares jumped 81.5% to close at $0.31 on Tuesday. Rubicon Technology, Inc. (NASDAQ: RBCN) shares surged 66.1% to settle at $15.05 on Tuesday after the company announced that it entered into a definitive stock purchase and sale agreement with Janel...
-
Needham Slashes Revenue, Earnings Projections, Price Targets of Majority Semiconductor Stocks: Key Takeaways
Tuesday, July 5, 2022 - 4:03pm | 554Needham analyst N. Quinn Bolton saw a slowdown in demand across most end markets coupled with several quarters of inventory purge is likely to significantly decrease semiconductor sales in C2H22 and 2023 from original base case estimates. His data analysis and other macro influences...
-
Federal Judge Says McKesson, AmerisourceBergen, Cardinal Health Not Responsible For Opioid Epidemic: Report
Tuesday, July 5, 2022 - 7:32am | 311Federal judge David Faber rejected the efforts to force McKesson Corp (NYSE: MCK), AmerisourceBergen Corp (NYSE: ABC), and Cardinal Health Inc (NYSE: CAH) to pay $2.5 billion for the opioid crisis. The judge ruled that the drug distributors are not responsible for...
-
Akerna Shares Dip 53%, Here's 78 Biggest Movers From Yesterday
Friday, July 1, 2022 - 4:52am | 2531Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical study of REVTx-99b for the treatment of allergic rhinitis. Ensysce Biosciences...
-
Why Is NeuroSense Therapeutics Jumping By 45%? 64 Stocks Moving In Thursday's Mid-Day Session
Thursday, June 30, 2022 - 12:03pm | 1982Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) jumped 171.3% to $1.70 after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical study of REVTx-99b for the treatment of allergic rhinitis. NeuroSense Therapeutics Ltd. (...